Cargando…
Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN
BACKGROUND AND OBJECTIVES: Acute kidney injury (AKI) is common among hospitalized patients with COVID-19 and associated with worse prognosis. The Spanish Society of Nephrology created the AKI-COVID Registry to characterize the population admitted for COVID-19 that developed AKI in Spanish hospitals....
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Nefrología. Published by Elsevier España, S.L.U.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076078/ https://www.ncbi.nlm.nih.gov/pubmed/37359780 http://dx.doi.org/10.1016/j.nefro.2023.03.008 |
_version_ | 1785020058643202048 |
---|---|
author | Salgueira, Mercedes Almenara, Marina Gutierrez-Pizarraya, Antonio Belmar, Lara Labrador, Pedro Jesús Melero, Rosa Serrano, María Luisa Portolés, José María Molina, Alicia Poch, Esteban Ramos, Natalia Lloret, María Jesús Echarri, Rocío Díaz Mancebo, Raquel González-Lara, Diego Mauricio Sánchez, Jesús Emilio Soler, María José |
author_facet | Salgueira, Mercedes Almenara, Marina Gutierrez-Pizarraya, Antonio Belmar, Lara Labrador, Pedro Jesús Melero, Rosa Serrano, María Luisa Portolés, José María Molina, Alicia Poch, Esteban Ramos, Natalia Lloret, María Jesús Echarri, Rocío Díaz Mancebo, Raquel González-Lara, Diego Mauricio Sánchez, Jesús Emilio Soler, María José |
author_sort | Salgueira, Mercedes |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Acute kidney injury (AKI) is common among hospitalized patients with COVID-19 and associated with worse prognosis. The Spanish Society of Nephrology created the AKI-COVID Registry to characterize the population admitted for COVID-19 that developed AKI in Spanish hospitals. The need of renal replacement therapy (RRT) therapeutic modalities, and mortality in these patients were assessed. MATERIAL AND METHOD: In a retrospective study, we analyzed data from the AKI-COVID Registry, which included patients hospitalized in 30 Spanish hospitals from May 2020 to November 2021. Clinical and demographic variables, factors related to the severity of COVID-19 and AKI, and survival data were recorded. A multivariate regression analysis was performed to study factors related to RRT and mortality. RESULTS: Data from 730 patients were recorded. A total of 71.9% were men, with a mean age of 70 years (60–78), 70.1% were hypertensive, 32.9% diabetic, 33.3% with cardiovascular disease and 23.9% had some degree of chronic kidney disease (CKD). Pneumonia was diagnosed in 94.6%, requiring ventilatory support in 54.2% and admission to the ICU in 44.1% of cases. The median time from the onset of COVID-19 symptoms to the appearance of AKI (37.1% KDIGO I, 18.3% KDIGO II, 44.6% KDIGO III) was 6 days (4–10). A total of 235 (33.9%) patients required RRT: 155 patients with continuous renal replacement therapy, 89 alternate-day dialysis, 36 daily dialysis, 24 extended hemodialysis and 17 patients with hemodiafiltration. Smoking habit (OR 3.41), ventilatory support (OR 20.2), maximum creatinine value (OR 2.41) and time to AKI onset (OR 1.13) were predictors of the need for RRT; age was a protective factor (0.95). The group without RRT was characterized by older age, less severe AKI, shorter kidney injury onset and recovery time (p < 0.05). 38.6% of patients died during hospitalization; serious AKI and RRT were more frequent in the death group. In the multivariate analysis, age (OR 1.03), previous chronic kidney disease (OR 2.21), development of pneumonia (OR 2.89), ventilatory support (OR 3.34) and RRT (OR 2.28) were predictors of mortality while chronic treatment with ARBs was identified as a protective factor (OR 0.55). CONCLUSIONS: Patients with AKI during hospitalization for COVID-19 had a high mean age, comorbidities and severe infection. We defined two different clinical patterns: an AKI of early onset, in older patients that resolves in a few days without the need for RRT; and another more severe pattern, with greater need for RRT, and late onset, which was related to greater severity of the infectious disease. The severity of the infection, age and the presence of CKD prior to admission were identified as risk factors for mortality in these patients. In addition chronic treatment with ARBs was identified as a protective factor for mortality. |
format | Online Article Text |
id | pubmed-10076078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100760782023-04-06 Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN Salgueira, Mercedes Almenara, Marina Gutierrez-Pizarraya, Antonio Belmar, Lara Labrador, Pedro Jesús Melero, Rosa Serrano, María Luisa Portolés, José María Molina, Alicia Poch, Esteban Ramos, Natalia Lloret, María Jesús Echarri, Rocío Díaz Mancebo, Raquel González-Lara, Diego Mauricio Sánchez, Jesús Emilio Soler, María José Nefrologia Original BACKGROUND AND OBJECTIVES: Acute kidney injury (AKI) is common among hospitalized patients with COVID-19 and associated with worse prognosis. The Spanish Society of Nephrology created the AKI-COVID Registry to characterize the population admitted for COVID-19 that developed AKI in Spanish hospitals. The need of renal replacement therapy (RRT) therapeutic modalities, and mortality in these patients were assessed. MATERIAL AND METHOD: In a retrospective study, we analyzed data from the AKI-COVID Registry, which included patients hospitalized in 30 Spanish hospitals from May 2020 to November 2021. Clinical and demographic variables, factors related to the severity of COVID-19 and AKI, and survival data were recorded. A multivariate regression analysis was performed to study factors related to RRT and mortality. RESULTS: Data from 730 patients were recorded. A total of 71.9% were men, with a mean age of 70 years (60–78), 70.1% were hypertensive, 32.9% diabetic, 33.3% with cardiovascular disease and 23.9% had some degree of chronic kidney disease (CKD). Pneumonia was diagnosed in 94.6%, requiring ventilatory support in 54.2% and admission to the ICU in 44.1% of cases. The median time from the onset of COVID-19 symptoms to the appearance of AKI (37.1% KDIGO I, 18.3% KDIGO II, 44.6% KDIGO III) was 6 days (4–10). A total of 235 (33.9%) patients required RRT: 155 patients with continuous renal replacement therapy, 89 alternate-day dialysis, 36 daily dialysis, 24 extended hemodialysis and 17 patients with hemodiafiltration. Smoking habit (OR 3.41), ventilatory support (OR 20.2), maximum creatinine value (OR 2.41) and time to AKI onset (OR 1.13) were predictors of the need for RRT; age was a protective factor (0.95). The group without RRT was characterized by older age, less severe AKI, shorter kidney injury onset and recovery time (p < 0.05). 38.6% of patients died during hospitalization; serious AKI and RRT were more frequent in the death group. In the multivariate analysis, age (OR 1.03), previous chronic kidney disease (OR 2.21), development of pneumonia (OR 2.89), ventilatory support (OR 3.34) and RRT (OR 2.28) were predictors of mortality while chronic treatment with ARBs was identified as a protective factor (OR 0.55). CONCLUSIONS: Patients with AKI during hospitalization for COVID-19 had a high mean age, comorbidities and severe infection. We defined two different clinical patterns: an AKI of early onset, in older patients that resolves in a few days without the need for RRT; and another more severe pattern, with greater need for RRT, and late onset, which was related to greater severity of the infectious disease. The severity of the infection, age and the presence of CKD prior to admission were identified as risk factors for mortality in these patients. In addition chronic treatment with ARBs was identified as a protective factor for mortality. Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. 2023-04-06 /pmc/articles/PMC10076078/ /pubmed/37359780 http://dx.doi.org/10.1016/j.nefro.2023.03.008 Text en © 2023 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Salgueira, Mercedes Almenara, Marina Gutierrez-Pizarraya, Antonio Belmar, Lara Labrador, Pedro Jesús Melero, Rosa Serrano, María Luisa Portolés, José María Molina, Alicia Poch, Esteban Ramos, Natalia Lloret, María Jesús Echarri, Rocío Díaz Mancebo, Raquel González-Lara, Diego Mauricio Sánchez, Jesús Emilio Soler, María José Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN |
title | Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN |
title_full | Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN |
title_fullStr | Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN |
title_full_unstemmed | Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN |
title_short | Caracterización de la población con fracaso renal agudo durante la hospitalización por COVID-19 en España: tratamiento renal sustitutivo y mortalidad. Datos del Registro FRA-COVID SEN |
title_sort | caracterización de la población con fracaso renal agudo durante la hospitalización por covid-19 en españa: tratamiento renal sustitutivo y mortalidad. datos del registro fra-covid sen |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076078/ https://www.ncbi.nlm.nih.gov/pubmed/37359780 http://dx.doi.org/10.1016/j.nefro.2023.03.008 |
work_keys_str_mv | AT salgueiramercedes caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT almenaramarina caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT gutierrezpizarrayaantonio caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT belmarlara caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT labradorpedrojesus caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT melerorosa caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT serranomarialuisa caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT portolesjosemaria caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT molinaalicia caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT pochesteban caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT ramosnatalia caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT lloretmariajesus caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT echarrirocio caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT diazmanceboraquel caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT gonzalezlaradiegomauricio caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT sanchezjesusemilio caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen AT solermariajose caracterizaciondelapoblacionconfracasorenalagudodurantelahospitalizacionporcovid19enespanatratamientorenalsustitutivoymortalidaddatosdelregistrofracovidsen |